BioSpace News Archive

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5th at 2:40 pm Eastern time.

Illumina, Inc. (NASDAQ: ILMN) has committed US $60 million in sequencing capabilities to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation and other public and private entities

For six years, the Multiple Sclerosis Association of America has been honored to host our annual Improving Lives Benefit in-person, raising funds for the MS community.

Transparency Market Research has published a new report titled, “Synthetic Biology Market”. According to the report, the global synthetic biology market was valued at US$ 4.96 Bn in 2018 and is projected to expand at a CAGR of 26.3% from 2019 to 2027.

Transparency Market Research has published a new report titled, ‘Osteoporosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Pneumonia vaccines are recommended for adults and children for a wide range of clinical conditions. The bacteria Streptococcus pneumoniae is responsible for pneumococcal infections causing otitis media, bacteremia, pneumonia, and meningitis.

Transparency Market Research has published a new report titled, ‘Inhalation and Nasal Sprays Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Disposable face masks are witnessing higher demand for themselves in current times because of the COVID-19 pandemic. These products are used to protect the face and nose from contamination.

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced that they received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Biologics License Application seeking accelerated approval of pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease.

DIC Corporation has completed investment in Vaxa Technologies Ltd., a biotech startup headquartered in Rosh Pina, Israel, as part of a strategic expansion of DIC businesses around health food and other algae-derived products.